Andreas Katsuya Lauer

Andreas Katsuya Lauer

Auto-generated profile, based on publicly available information

Andreas Katsuya Lauer

Casey Eye Institute, Oregon Health and Science University, Portland, OR, USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2017 in Ophthalmology Retina
Verified
Journal Article
Closed access
AFAmbar Faridi
Ambar Faridi
YJYali Jia
Yali Jia
SGSimon S. Gao
Simon S. Gao
DHDavid Huang
David Huang
KBKavita V. Bhavsar
Kavita V. Bhavsar
SBSteven T. Bailey
Steven T. Bailey

4 March 2022 in American Journal of Ophthalmology
Verified
Journal Article
Open access
MPMaria A. Parker
Maria A. Parker
LELaura R. Erker
Laura R. Erker
IAIsabelle Audo
Isabelle Audo
DCDongseok Choi
Dongseok Choi
SMSaddek Mohand-Said
Saddek Mohand-Said
PYPaul Yang
Paul Yang
To report on the safety of the first five cohorts of a gene therapy trial using recombinant equine infectious anemia virus expressing ABCA4 (EIAV-ABCA4) in adults with Stargardt Dystrophy (SD) due to mutations in ABCA4. Nonrandomized multicenter phase I/IIa clinical trial. Patients received a subretinal injection of EIAVABCA4 in the worse-seeing eye at three dose levels and were followed for three years after treatment. The primary end point was ocular and systemic adverse events. The secondary endpoints were best-corrected visual acuity (BCVA), static perimetry (SP), kinetic perimetry (KP), total field hill of vision (VTOT), full field electroretinogram (ffERG), multifocal ERG (mfERG), color fundus photography (CFP), short-wavelength fundus autofluorescence (FAF), and spectral domain optical coherence tomography (SD-OCT). The subretinal injections were well-tolerated by all 22 patients across three dose levels. There was one case of a treatment-related ophthalmic serious adverse event in the form of chronic ocular hypertension. The most common adverse events were associated with the surgical procedure. In one patient treated with the highest dose, there was a significant decline in the number of macular flecks as compared to the untreated eye. However, in six patients hypoautofluorescent changes were worse in the treated eye than the untreated eye. Of these, one patient had retinal pigment epithelium (RPE) atrophy that was characteristic of tissue damage likely associated with bleb induction. No patients had any clinically significant changes in BCVA, SP, KP, VTOT, ffERG, or mfERG attributable to the treatment. Subretinal treatment with EIAV-ABCA4 was well tolerated with only one case of ocular hypertension. No clinically significant changes in visual function tests were found to be attributable to the treatment. However, 27% of treated eyes showed exacerbation of RPE atrophy on FAF. There was significant reduction in macular flecks in one treated eye from the highest dose cohort. Additional follow-up and continued investigation in more patients will be required to fully characterize the safety and efficacy of EIAV-ABCA4.

4 March 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
YEYulia Eygeris
Yulia Eygeris
MGMohit Gupta
Mohit Gupta
JKJeonghwan Kim
Jeonghwan Kim
AJAntony Jozic
Antony Jozic
MGMilan Gautam
Milan Gautam
GSGaurav Sahay
Gaurav Sahay
Lipid nanoparticles (LNPs) largely rely on ionizable lipids to yield successful nucleic acid delivery via electrostatic disruption of the endosomal membrane. Here, we report the identification and evaluation of ionizable lipids containing a thiophene moiety (Thio-lipids). The Thio-lipids can be readily synthesized via the Gewald reaction, allowing for modular lipid design with functional constituents at various positions of the thiophene ring. Through the rational design of ionizable lipid structure, we prepared 47 Thio-lipids and identified some structural criteria required in Thio-lipids for efficient mRNA (messenger RNA) encapsulation and delivery in vitro and in vivo. Notably, none of the tested lipids have a pH-response profile like traditional ionizable lipids, potentially due to the electron delocalization in the thiophene core. Placement of the tails and localization of the ionizable headgroup in the thiophene core can endow the nanoparticles with the capability to reach various tissues. Using high-throughput formulation and barcoding techniques, we optimized the formulations to select two top lipids— 20b and 29d —and investigated their biodistribution in mice. Lipid 20b enabled LNPs to transfect the liver and spleen, and 29d LNP transfected the lung and spleen. Unexpectedly, LNP with lipid 20b was especially potent in mRNA delivery to the retina with no acute toxicity, leading to the successful delivery to the photoreceptors and retinal pigment epithelium in non-human primates.

1 May 2020 in International Journal of Retina and Vitreous
Verified
Journal Article
Open access
PDF file
HVHuber M. Vasconcelos
Huber M. Vasconcelos
BLBrandon J. Lujan
Brandon J. Lujan
MPMark E. Pennesi
Mark E. Pennesi
PYPaul Yang
Paul Yang
ALAndreas K. Lauer
Andreas K. Lauer
Background: To analyze intraoperative OCT (iOCT) findings during subretinal gene therapy. Methods: A single-center, retrospective, observational, case series study of twenty one eyes submitted to subretinal gene therapy. Intrasurgical high definition videos were included for analyzes. Cases with absence of iOCT video or unsuccessful bleb creation were excluded. Sharp needle tip (SNT) or blunted needle tip (BNT) and their interaction with neurosensory retina were evaluated. Presence of subretinal air bubbles, visible opened retinotomy, and medication reflux were also correlated and analyzed. Results: Nineteen of twenty-one eyes were included. Of the two excluded eyes, subretinal bleb creation was unsuccessful in one and technical issues prevented OCT image acquisition in the other. Immediately before subretinal injection, needle indention/penetration of the neurosensory retina with temporary indentation of the RPE/choroid was evident in 16 (84%) of the 19 eyes. Complete RPE/choroid indentation was needed with BNT use compared to SNT (p = 0.0114). An open retinotomy was identified in 14 (74%) of 19 eyes at the conclusion of bleb injection and was more commonly associated with SNT (p = 0.0108). Conclusions: iOCT provides valuable real-time feedback of cross-sectional retinal anatomy during subretinal gene therapy surgeries. The type of needle tip and its use during the gene therapy procedure seems to influence in the bleb creation and presence of visible open retinotomy. Further studies of iOCT findings during gene therapy delivery procedures are likely to help refine the surgical technique.

1 February 1999 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
ALAndreas Katsuya Lauer
Andreas Katsuya Lauer
JWJohn L. Wobig
John L. Wobig
WSWilliam T. Shults
William T. Shults
ENEdward A. Neuwelt
Edward A. Neuwelt
MWMatthew W. Wilson
Matthew W. Wilson

4 December 2024 in American Journal of Ophthalmology
Verified
Journal Article
Open access
PYPaul Yang
Paul Yang
David BirchDavid Birch
David Birch
ALAndreas Lauer
Andreas Lauer
RSRobert Sisk
Robert Sisk
RARajiv Anand
Rajiv Anand
NWNadia K. Waheed
Nadia K. Waheed
To evaluate the safety and efficacy of subretinal gene therapy using AGTC-501 (rAAV2tYF-GRK1-RPGR) in male participants with X-linked retinitis pigmentosa (XLRP). Phase 1/2, open-label, dose-escalation study. Setting: Four centers in the United States. Patient or Study Population: Twenty-nine males with XLRP and confirmed pathogenic RPGR variants. Mean age was 31.6 years (range 15-55). Subretinal injection of AGTC-501 at doses ranging from 2.48 × 1010 to 1.99 × 1012 vg/eye administered in one eye per participant. Subretinal injection sites initially targeted the peripheral retina and then transitioned to the macula with successive cohorts. Treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), laboratory parameters, and immunological responses. Efficacy was evaluated by mesopic microperimetry mean sensitivity. All 29 participants experienced ≥1 TEAE. Eleven (38%) experienced ≥1 grade 3 TEAE. Six (21%) experienced ≥1 ocular SAE related to AGTC-501, including retinal detachment (n = 4), subcapsular cataract (n = 1), and glaucoma (n = 1). Two (6.9%) experienced non-ocular treatment-emergent SAEs. Immunological findings did not indicate safety concerns. Three of 4 participants at the highest dose exhibited concerning retinal pigment epithelial changes. Half the participants at the highest tolerated dose (6.8 × 1011vg/eye) maintained ≥7 dB improvement in ≥5 loci at 24 months. Subretinal AGTC-501 was generally well-tolerated. Despite all participants experiencing at least one TEAE, most of these events were mild in nature, exhibited complete resolution, and were associated with the subretinal injection procedure itself rather than the study agent. The highest dose exhibited an unfavorable risk-benefit profile due to the development of RPE changes. Although this group had the highest improvement in retinal sensitivity, our team has decided not to continue this dose in future clinical trials. Preliminary efficacy was observed at the maximum tolerated dose. Further studies are warranted to assess long-term safety and efficacy of AGTC-501 for XLRP treatment.